Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
317 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hepatitis B - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hepatitis B - Pipeline Review, H2 2014', provides an overview of the Hepatitis B's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hepatitis B - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hepatitis B and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hepatitis B pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis B - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Hepatitis B Overview 12 Therapeutics Development 13 Pipeline Products for Hepatitis B - Overview 13 Pipeline Products for Hepatitis B - Comparative Analysis 14 Hepatitis B - Therapeutics under Development by Companies 15 Hepatitis B - Therapeutics under Investigation by Universities/Institutes 23 Hepatitis B - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Unknown Stage Products 27 Hepatitis B - Products under Development by Companies 28 Hepatitis B - Products under Investigation by Universities/Institutes 36 Hepatitis B - Companies Involved in Therapeutics Development 37 Abivax 37 AiCuris GmbH & Co. KG 38 Akshaya Bio Inc. 39 Alnylam Pharmaceuticals, Inc. 40 AlphaMab Co., Ltd 41 AltraVax Inc. 42 Amarna Therapeutics B.V. 43 Arrowhead Research Corporation 44 Assembly Biosciences, Inc. 45 Beijing Minhai Biotechnology Co., Ltd 46 Benitec Biopharma Limited 47 Big DNA Ltd. 48 BioDiem Ltd 49 Biological E. Limited 50 BioStar Pharmaceuticals, Inc. 51 Bolder Biotechnology, Inc. 52 Bukwang Pharm.Co., Ltd. 53 CEL-SCI Corporation 54 Celltrion, Inc. 55 Chiasma, Inc. 56 Chimerix, Inc. 57 Chongqing Zhifei Biological Products Co., Ltd. 58 ChronTech Pharma AB 59 Colby Pharmaceutical Company 60 Dynavax Technologies Corporation 61 F. Hoffmann-La Roche Ltd. 62 GeneCure LLC 63 Genexine, Inc. 64 Gilead Sciences, Inc. 65 GlaxoSmithKline plc 66 GlobalAcorn 67 Green Cross Corporation 68 HEC Pharm Co., Ltd. 69 Humabs BioMed SA 70 Ildong Pharmaceutical Co., Ltd. 71 Immune Targeting Systems (ITS) Ltd. 72 Immunovaccine, Inc. 73 Inbiopro Solutions Pvt. Ltd. 74 Indian Immunologicals Limited 75 Isis Pharmaceuticals, Inc. 76 Johnson & Johnson 77 Leukocare AG 78 LG Life Sciences, Ltd. 79 Ligand Pharmaceuticals, Inc. 80 Mologen AG 81 Mucosis B.V. 82 NeuroVive Pharmaceutical AB 83 Novira Therapeutics, Inc. 84 Panacea Biotec Limited 85 PharmaEssentia Corporation 86 REPLICor Inc. 87 RFS Pharma, LLC 88 Romark Laboratories, L.C. 89 Sanofi Pasteur SA 90 Scynexis, Inc. 91 Seek 92 Sinovac Biotech Ltd. 93 SK Chemicals Co., Ltd. 94 SomaGenics Inc. 95 Spring Bank Pharmaceuticals, Inc. 96 TCM Biotech International Corp 97 Tekmira Pharmaceuticals Corp. 98 TetraLogic Pharmaceuticals 99 Therametrics holding AG 100 THERAVECTYS SA 101 Transgene SA 102 Uni-Bio Science Group Ltd. 103 Vaxart, Inc. 104 Vaxine Pty Ltd 105 VLP Biotech, Inc. 106 WaterStone Pharmaceuticals, Inc. 107 Hepatitis B - Therapeutics Assessment 108 Assessment by Monotherapy Products 108 Assessment by Combination Products 109 Assessment by Target 110 Assessment by Mechanism of Action 113 Assessment by Route of Administration 115 Assessment by Molecule Type 117 Drug Profiles 119 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine - Drug Profile 119 ABX-196 - Drug Profile 121 ABX-203 - Drug Profile 122 acALY-18 - Drug Profile 123 AGX-1009 - Drug Profile 124 AIC-649 - Drug Profile 125 ALN-HBV - Drug Profile 126 amdoxovir - Drug Profile 127 ARC-520 - Drug Profile 128 BBT-012 - Drug Profile 130 BDNA-001 - Drug Profile 131 besifovir - Drug Profile 132 birinapant - Drug Profile 134 CEL-1000 - Drug Profile 137 ChronVac-B - Drug Profile 139 clevudine - Drug Profile 140 CMX-157 - Drug Profile 142 CpAM Gen-1 - Drug Profile 143 CpAM Gen-2 - Drug Profile 144 CPI-43132 - Drug Profile 145 Creaferon - Drug Profile 146 CTP-24 - Drug Profile 147 cTP-5 - Drug Profile 148 DasKloster-0039-01 - Drug Profile 149 Dendritic Cell Therapy for Hepatitis B - Drug Profile 150 diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine - Drug Profile 151 diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine - Drug Profile 152 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 153 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 154 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 155 Drug for Hepatitis B - Drug Profile 156 Drugs for Hepatitis B Virus Infections - Drug Profile 157 DVR-23 - Drug Profile 158 FP-02 - Drug Profile 159 GA-5NM-HBV - Drug Profile 160 GC-1102 - Drug Profile 161 Gene Therapy for Hepatitis B and Hepatitis C - Drug Profile 162 GLS-4 - Drug Profile 163 GS-4774 - Drug Profile 164 GS-9620 - Drug Profile 165 GSK-217744 - Drug Profile 167 GSK-2231392A - Drug Profile 168 HB-110E - Drug Profile 169 Hepabulin - Drug Profile 171 hepatitis A + hepatitis B vaccine - Drug Profile 172 Hepatitis B Surface Antigen Secretion Inhibitor - Drug Profile 173 Hepatitis B Vaccine - Drug Profile 174 hepatitis B vaccine - Drug Profile 176 hepatitis B vaccine - Drug Profile 177 hepatitis B vaccine - Drug Profile 178 hepatitis B vaccine - Drug Profile 179 hepatitis B vaccine - Drug Profile 180 hepatitis B vaccine - Drug Profile 181 hepatitis B vaccine - Drug Profile 182 hepatitis B vaccine - Drug Profile 183 hepatitis B vaccine - Drug Profile 184 hepatitis B vaccine - Drug Profile 185 hepatitis B vaccine - Drug Profile 186 hepatitis B vaccine - Drug Profile 187 hepatitis B vaccine - Drug Profile 188 hepatitis B vaccine - Drug Profile 189 hepatitis B vaccine - Drug Profile 190 hepatitis B vaccine - Drug Profile 191 hepatitis B vaccine - Drug Profile 192 hepatitis B vaccine (HBcAg and HBsAg) - Drug Profile 193 hepatitis B vaccine (HBcAg) - Drug Profile 194 hepatitis-B vaccine - Drug Profile 195 HepB Vaccine - Drug Profile 196 HepB-nRNA - Drug Profile 197 Hepbarna - Drug Profile 198 IBPB-006IA - Drug Profile 200 INO-1800 - Drug Profile 201 interferon alfa-2a - Drug Profile 203 interferon alfa-2b - Drug Profile 204 ISIS-HBVRx - Drug Profile 205 JVRS-100 + HBV Vaccine - Drug Profile 206 KN-003 - Drug Profile 207 KW-1 - Drug Profile 208 KW-2 - Drug Profile 209 MGN-1333 - Drug Profile 210 Monoclonal Antibody for HBV Infections - Drug Profile 211 Monoclonal Antibody for Hepatitis B - Drug Profile 212 Myrcludex-B - Drug Profile 213 Novaferon - Drug Profile 215 NVP-018 - Drug Profile 217 NVR-3778 - Drug Profile 218 PEG-IFN-SA - Drug Profile 219 peginterferon alfa-2b - Drug Profile 220 pradefovir mesylate - Drug Profile 222 Prophylactic Hepatitis B Vaccine - Drug Profile 223 Protein for Hepatitis C, Hepatitis B and Cancer - Drug Profile 224 REP-9-AC - Drug Profile 225 REP-9-AC' - Drug Profile 227 RG-7795 - Drug Profile 229 RM-5038 - Drug Profile 231 RNAi Oligonucleotide for Hepatitis B - Drug Profile 232 SB-9200 - Drug Profile 233 SCY-635 - Drug Profile 235 Small Molecule for Hepatitis B - Drug Profile 237 Small Molecule for Liver Cancer and Hepatitis B - Drug Profile 238 Small Molecule to Inhibit Capsid Protein for Hepatitis B - Drug Profile 239 Small Molecule to Inhibit cccDNA for Hepatitis B - Drug Profile 240 Small Molecules for Bacterial and Viral Infections - Drug Profile 241 Small Molecules for Hepatitis B - Drug Profile 243 Small Molecules for Hepatitis B - Drug Profile 244 Small Molecules for Hepatitis B Infections - Drug Profile 245 Small Molecules for Viral Infections - Drug Profile 246 Small Molecules to Inhibit HBx for Hepatitis B and Hepatocellular Carcinoma - Drug Profile 247 Small Molecules to Inhibit Reverse Transcriptase for Hepatitis B - Drug Profile 248 Small Molecules to Target Caspase and Inhibitor Of Apoptosis Protein for Cancer and Hepatitis B Virus Infection - Drug Profile 249 TCM-800B - Drug Profile 250 tenofovir alafenamide - Drug Profile 251 TG-1050 - Drug Profile 252 Therapeutic Hepatitis B Vaccine - Drug Profile 253 TKM-HBV - Drug Profile 254 Vaccine for Cancer and Hepatitis B - Drug Profile 255 Vaccine for Hepatitis - Drug Profile 256 W-28F - Drug Profile 257 Y-101 - Drug Profile 258 Hepatitis B - Recent Pipeline Updates 259 Hepatitis B - Dormant Projects 292 Hepatitis B - Discontinued Products 299 Hepatitis B - Product Development Milestones 300 Featured News & Press Releases 300 Appendix 308 Methodology 308 Coverage 308 Secondary Research 308 Primary Research 308 Expert Panel Validation 308 Contact Us 309 Disclaimer 309
List of Tables Number of Products under Development for Hepatitis B, H2 2014 21 Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2014 22 Number of Products under Development by Companies, H2 2014 24 Number of Products under Development by Companies, H2 2014 (Contd..1) 25 Number of Products under Development by Companies, H2 2014 (Contd..2) 26 Number of Products under Development by Companies, H2 2014 (Contd..3) 27 Number of Products under Development by Companies, H2 2014 (Contd..4) 28 Number of Products under Development by Companies, H2 2014 (Contd..5) 29 Number of Products under Development by Companies, H2 2014 (Contd..6) 30 Number of Products under Investigation by Universities/Institutes, H2 2014 31 Comparative Analysis by Late Stage Development, H2 2014 32 Comparative Analysis by Clinical Stage Development, H2 2014 33 Comparative Analysis by Early Stage Development, H2 2014 34 Comparative Analysis by Unknown Stage Development, H2 2014 35 Products under Development by Companies, H2 2014 36 Products under Development by Companies, H2 2014 (Contd..1) 37 Products under Development by Companies, H2 2014 (Contd..2) 38 Products under Development by Companies, H2 2014 (Contd..3) 39 Products under Development by Companies, H2 2014 (Contd..4) 40 Products under Development by Companies, H2 2014 (Contd..5) 41 Products under Development by Companies, H2 2014 (Contd..6) 42 Products under Development by Companies, H2 2014 (Contd..7) 43 Products under Investigation by Universities/Institutes, H2 2014 44 Hepatitis B - Pipeline by Abivax, H2 2014 45 Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H2 2014 46 Hepatitis B - Pipeline by Akshaya Bio Inc., H2 2014 47 Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 48 Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2014 49 Hepatitis B - Pipeline by AltraVax Inc., H2 2014 50 Hepatitis B - Pipeline by Amarna Therapeutics B.V., H2 2014 51 Hepatitis B - Pipeline by Arrowhead Research Corporation, H2 2014 52 Hepatitis B - Pipeline by Assembly Biosciences, Inc., H2 2014 53 Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 54 Hepatitis B - Pipeline by Benitec Biopharma Limited, H2 2014 55 Hepatitis B - Pipeline by Big DNA Ltd., H2 2014 56 Hepatitis B - Pipeline by BioDiem Ltd, H2 2014 57 Hepatitis B - Pipeline by Biological E. Limited, H2 2014 58 Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H2 2014 59 Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H2 2014 60 Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H2 2014 61 Hepatitis B - Pipeline by CEL-SCI Corporation, H2 2014 62 Hepatitis B - Pipeline by Celltrion, Inc., H2 2014 63 Hepatitis B - Pipeline by Chiasma, Inc., H2 2014 64 Hepatitis B - Pipeline by Chimerix, Inc., H2 2014 65 Hepatitis B - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 66 Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2014 67 Hepatitis B - Pipeline by Colby Pharmaceutical Company, H2 2014 68 Hepatitis B - Pipeline by Dynavax Technologies Corporation, H2 2014 69 Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 70 Hepatitis B - Pipeline by GeneCure LLC, H2 2014 71 Hepatitis B - Pipeline by Genexine, Inc., H2 2014 72 Hepatitis B - Pipeline by Gilead Sciences, Inc., H2 2014 73 Hepatitis B - Pipeline by GlaxoSmithKline plc, H2 2014 74 Hepatitis B - Pipeline by GlobalAcorn, H2 2014 75 Hepatitis B - Pipeline by Green Cross Corporation, H2 2014 76 Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2014 77 Hepatitis B - Pipeline by Humabs BioMed SA, H2 2014 78 Hepatitis B - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 79 Hepatitis B - Pipeline by Immune Targeting Systems (ITS) Ltd., H2 2014 80 Hepatitis B - Pipeline by Immunovaccine, Inc., H2 2014 81 Hepatitis B - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 82 Hepatitis B - Pipeline by Indian Immunologicals Limited, H2 2014 83 Hepatitis B - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 84 Hepatitis B - Pipeline by Johnson & Johnson, H2 2014 85 Hepatitis B - Pipeline by Leukocare AG, H2 2014 86 Hepatitis B - Pipeline by LG Life Sciences, Ltd., H2 2014 87 Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 88 Hepatitis B - Pipeline by Mologen AG, H2 2014 89 Hepatitis B - Pipeline by Mucosis B.V., H2 2014 90 Hepatitis B - Pipeline by NeuroVive Pharmaceutical AB, H2 2014 91 Hepatitis B - Pipeline by Novira Therapeutics, Inc., H2 2014 92 Hepatitis B - Pipeline by Panacea Biotec Limited, H2 2014 93 Hepatitis B - Pipeline by PharmaEssentia Corporation, H2 2014 94 Hepatitis B - Pipeline by REPLICor Inc., H2 2014 95 Hepatitis B - Pipeline by RFS Pharma, LLC, H2 2014 96 Hepatitis B - Pipeline by Romark Laboratories, L.C., H2 2014 97 Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2014 98 Hepatitis B - Pipeline by Scynexis, Inc., H2 2014 99 Hepatitis B - Pipeline by Seek, H2 2014 100 Hepatitis B - Pipeline by Sinovac Biotech Ltd., H2 2014 101 Hepatitis B - Pipeline by SK Chemicals Co., Ltd., H2 2014 102 Hepatitis B - Pipeline by SomaGenics Inc., H2 2014 103 Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014 104 Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2014 105 Hepatitis B - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 106 Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2014 107 Hepatitis B - Pipeline by Therametrics holding AG, H2 2014 108 Hepatitis B - Pipeline by THERAVECTYS SA, H2 2014 109 Hepatitis B - Pipeline by Transgene SA, H2 2014 110 Hepatitis B - Pipeline by Uni-Bio Science Group Ltd., H2 2014 111 Hepatitis B - Pipeline by Vaxart, Inc., H2 2014 112 Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2014 113 Hepatitis B - Pipeline by VLP Biotech, Inc., H2 2014 114 Hepatitis B - Pipeline by WaterStone Pharmaceuticals, Inc., H2 2014 115 Assessment by Monotherapy Products, H2 2014 116 Assessment by Combination Products, H2 2014 117 Number of Products by Stage and Target, H2 2014 119 Number of Products by Stage and Mechanism of Action, H2 2014 122 Number of Products by Stage and Route of Administration, H2 2014 124 Number of Products by Stage and Molecule Type, H2 2014 126 Hepatitis B Therapeutics - Recent Pipeline Updates, H2 2014 267 Hepatitis B - Dormant Projects, H2 2014 300 Hepatitis B - Dormant Projects (Contd..1), H2 2014 301 Hepatitis B - Dormant Projects (Contd..2), H2 2014 302 Hepatitis B - Dormant Projects (Contd..3), H2 2014 303 Hepatitis B - Dormant Projects (Contd..4), H2 2014 304 Hepatitis B - Dormant Projects (Contd..5), H2 2014 305 Hepatitis B - Dormant Projects (Contd..6), H2 2014 306 Hepatitis B - Discontinued Products, H2 2014 307
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.